Table 5.
Omp- and/or HP 0305-, N= 209 | Omp+ and HP 0305+, N= 282 | ||||
---|---|---|---|---|---|
Metabolites | OR (95%CI) | P | OR (95%CI) | P | P interaction |
orotate | 1.97 (1.27–3.05) | 0.00237 | 1.60 (1.15–2.22) | 0.00518 | 0.42924 |
1-(1-enyl-palmitoyl)-GPE (P-16:0) | 1.53 (1.11–2.11) | 0.00921 | 1.65 (1.20–2.27) | 0.00196 | 0.72353 |
sphinganine | 1.51 (1.10–2.05) | 0.00998 | 1.61 (1.15–2.25) | 0.00544 | 0.77056 |
1-(1-enyl-stearoyl)-GPE (P-18:0) | 1.60 (1.13–2.25) | 0.00727 | 1.56 (1.13–2.15) | 0.00644 | 0.91327 |
glycerophosphoethanolamine | 1.58 (1.14–2.20) | 0.0067 | 1.52 (1.09–2.12) | 0.01285 | 0.86561 |
5alpha-pregnan-3beta,20beta-diol monosulfate | 1.43 (1.05–1.95) | 0.0225 | 1.44 (1.07–1.93) | 0.01579 | 0.97956 |
N6-methyllysine | 1.37 (0.99–1.91) | 0.06112 | 1.39 (1.04–1.87) | 0.02791 | 0.94965 |
3-hydroxypyridine sulfate | 0.68 (0.48–0.97) | 0.03273 | 0.66 (0.49–0.89) | 0.00648 | 0.91352 |
1-(1-enyl-oleoyl)-2-docosahexaenoyl-GPE (P-18:1/22:6) | 1.65 (1.11–2.45) | 0.0132 | 1.38 (1.06–1.79) | 0.01634 | 0.41561 |
1-palmitoyl-GPC (16:0) | 1.82 (1.30–2.55) | 4.61×10−4 | 1.12 (0.81–1.56) | 0.48253 | 0.03265 |
1-(1-enyl-palmitoyl)-GPC (P-16:0) | 1.70 (1.19–2.43) | 0.00346 | 1.21 (0.91–1.61) | 0.18623 | 0.11854 |
quinate | 0.76 (0.55–1.04) | 0.08682 | 0.66 (0.49–0.89) | 0.0068 | 0.47547 |
1-stearoyl-GPC (18:0) | 1.98 (1.36–2.87) | 3.25×10−4 | 1.11 (0.81–1.51) | 0.52083 | 0.01361 |
methylmalonate (MMA) | 1.53 (1.11–2.12) | 0.00926 | 1.33 (0.95–1.86) | 0.09316 | 0.54087 |
N-(2-furoyl) glycine | 0.75 (0.52–1.07) | 0.112 | 0.67 (0.49–0.92) | 0.01453 | 0.64005 |
5alpha-pregnan-diol disulfate | 1.52 (1.10–2.11) | 0.01103 | 1.30 (0.98–1.72) | 0.06981 | 0.41333 |
glutamate | 1.31 (0.96–1.80) | 0.08963 | 1.50 (1.08–2.10) | 0.01665 | 0.54464 |
cysteine | 0.77 (0.55–1.06) | 0.10464 | 0.71 (0.52–0.95) | 0.02192 | 0.69915 |
The covariates listed in Table 2 were included in the regression analysis.